"However, data are available from the AI0444-040 study, which tested the licensed regimen DCV+SOF+/-RBV over 24 weeks. In this study an SVR of 100% was observed in five treatment naive F3-F4 genotype 3 patients (note that only one received DCV+SOF+RBV, the others received DCV+SOF)."
